TRPV1, endocannabinoid, and opioid systems in analgesia: molecular mechanisms and drug development strategies
Canadian Journal of Physiology and Pharmacology · 01.01.2026 · 104 · 1-11
DOI: 10.1139/cjpp-2025-0328 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Canadian Journal of Physiology and Pharmacology, erschienen am 01.01.2026. Verfasst von Kaoutar Benkhraba und 2 weiteren Autor:innen. Beteiligte Einrichtung: Département de Biomédecine Vétérinaire, Faculté de Médecine Vétérinaire, Université de Montréal, Saint-Hyacinthe, QC, Canada. Hauptthemen laut MEDLINE: TRPV Cation Channels, Endocannabinoids, Analgesics, Opioid, Drug Development. Die Arbeit nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canada Research Chairs Program, National Sciences and Engineering Research Council of Canada.
Abstract (Originalsprache)
Pain modulation relies on complex molecular interactions among ion channels, G protein-coupled receptors, and intracellular signaling cascades. The Transient Receptor Potential Vanilloid 1 (TRPV1) channel serves as a polymodal detector and integrator of noxious stimuli, linking sensory transduction with broader neuromodulatory systems. This review delineates the mechanistic crosstalk between TRPV1, endocannabinoid, and opioid pathways in nociceptive regulation. TRPV1 activation by heat, protons, or endogenous lipids induces calcium influx and engages protein kinase C (PKC), protein kinase A (PKA), and mitogen-activated protein kinase (MAPK) pathways that modulate channel phosphorylation and neuronal excitability. Endocannabinoids such as anandamide act as dual CB 1 and TRPV1 agonists, establishing feedback loops that adjust nociceptive thresholds, while μ-opioid receptor activation inhibits adenylate cyclase and TRPV1 sensitization through Gi/o-mediated signaling. Given the recent progress in cryo-electron microscopy and molecular modeling, simulation studies have been possible, revealing key structural determinants underlying key receptor interactions. Integrating pharmacophore modeling, molecular docking, and artificial intelligence–based screening enables rational design of multi-target ligands that exploit TRPV1–endocannabinoid–opioid synergy. This mechanistic framework supports the development of next-generation analgesics that achieve potent, sustained, and safe modulation of nociceptive signaling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Département de Biomédecine Vétérinaire, Faculté de Médecine Vétérinaire, Université de Montréal, Saint-Hyacinthe, QC, Canada.
- Centre interdisciplinaire de recherche sur le cerveau et l'apprentissage (CIRCA), Université de Montréal, Montréal, QC, Canada.
ORCID-Profile: Francis Beaudry
Förderung
- Canada Research Chairs Program
- National Sciences and Engineering Research Council of Canada
Zitieren
APA
Benkhraba, K., Castaño, J., & Beaudry, F. (2026). TRPV1, endocannabinoid, and opioid systems in analgesia: molecular mechanisms and drug development strategies. Canadian Journal of Physiology and Pharmacology, 104, 1-11. https://doi.org/10.1139/cjpp-2025-0328
Vancouver
Benkhraba K, Castaño J, Beaudry F. TRPV1, endocannabinoid, and opioid systems in analgesia: molecular mechanisms and drug development strategies. Canadian Journal of Physiology and Pharmacology. 2026;104:1-11. doi:10.1139/cjpp-2025-0328
BibTeX
@article{Benkhraba2026,
author = {Benkhraba, Kaoutar and Castaño, Jesus D and Beaudry, Francis},
title = {TRPV1, endocannabinoid, and opioid systems in analgesia: molecular mechanisms and drug development strategies},
journal = {Canadian Journal of Physiology and Pharmacology},
year = {2026},
volume = {104},
pages = {1--11},
doi = {10.1139/cjpp-2025-0328}
}
EUVIMED